Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;14(4):868-871.
doi: 10.21037/tau-2025-45. Epub 2025 Apr 17.

The patients have spoken: how does enfortumab vedotin impact quality of life?

Jason R Brown  1   2
Affiliations
Editorial

The patients have spoken: how does enfortumab vedotin impact quality of life?

Jason R Brown. Transl Androl Urol. .
No abstract available

Keywords: Enfortumab vedotin (EV); advanced urothelial carcinoma (aUC); health-related quality of life; patient-reported outcomes (PROs).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-45/coif). J.R.B. has served on advisory boards for Pfizer, EMD Serono, and Johnson & Johnson. He is also on a speakers’ bureau for Merck. The author has no other conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

References

    1. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35. 10.1056/NEJMoa2035807 - DOI - PMC - PubMed
    1. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875-88. 10.1056/NEJMoa2312117 - DOI - PubMed
    1. Rosenberg JE, Powles T, Sonpavde GP, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 2023;34:1047-54. 10.1016/j.annonc.2023.08.016 - DOI - PubMed
    1. Rosenberg JE, Mamtani R, Sonpavde GP, et al. Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: a phase 3 trial of enfortumab vedotin versus chemotherapy. Eur Urol 2024;85:574-85. 10.1016/j.eururo.2024.01.007 - DOI - PMC - PubMed
    1. Van Hemelrijck M, Sparano F, Josephs D, et al. Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. BMC Urol 2019;19:86. 10.1186/s12894-019-0518-9 - DOI - PMC - PubMed

LinkOut - more resources